[{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma and Zylo Enter Into Joint Venture Agreement to Focus on the Development of Ketamine using ZTI\u2019s Z-pod\u2122 Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"University of Maryland","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psychedelics Company Silo Pharma Working on Time-Release and Dosage Ketamine Implant and Topical, Hoping to Deliver Steady Pain Relief for Four Million Fibromyalgia Sufferers","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Silo Pharma
The agreement aims to create a time-release ketamine implant, SP-26, which blocks the activity of the N-methyl-D-aspartate receptor (NMDAR), to treat fibromyalgia and other chronic pain conditions.
The agreement aims to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia, alongside development of SP-26, company's novel time-release topical formulation of ketamine.
In the most recent phase of this ongoing animal study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 (psilocybin) peptide-guided anti-arthritis drug versus the drug alone.
The joint venture will initially explore the clinical development of ketamine using ZTI’s Z-pod technology, but also provides for Silo Pharma to obtain an exclusive option for the clinical development of psilocybin using ZTI’s Z-pod technology as well.
The patent applications pertain to Silo Pharma’s novel and proprietary central nervous system (CNS) homing peptides for use in the therapeutic treatment of pain from neuroinflammation in cancer patients.